AADI - Aadi Bioscience, Inc. Stock Price, Fair Value and News

2.02USD+0.08 (+4.12%)Market Closed

Market Summary

USD2.02+0.08

Market Closed

4.12%

AADI Stock Price

View Fullscreen

AADI RSI Chart

AADI Valuation

Market Cap

49.6M

Price/Earnings (Trailing)

-0.75

Price/Sales (Trailing)

2.04

EV/EBITDA

0.21

Price/Free Cashflow

-0.78

AADI Price/Sales (Trailing)

AADI Profitability

EBT Margin

-264.70%

Return on Equity

-62.52%

Return on Assets

-49.66%

Free Cashflow Yield

-128.3%

AADI Fundamentals

AADI Revenue

Revenue (TTM)

24.4M

Rev. Growth (Yr)

21.03%

Rev. Growth (Qtr)

6.16%

AADI Earnings

Earnings (TTM)

-65.8M

Earnings Growth (Yr)

-16.93%

Earnings Growth (Qtr)

0.2%

Breaking Down AADI Revenue

Last 7 days

20.2%

Last 30 days

-7.3%

Last 90 days

16.1%

Trailing 12 Months

-73.9%

How does AADI drawdown profile look like?

AADI Financial Health

Current Ratio

4.72

AADI Investor Care

Shares Dilution (1Y)

0.54%

Diluted EPS (TTM)

-2.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	18.8M	21.5M	23.3M	24.4M
2022	14.3M	14.6M	14.9M	15.2M
2021	14.0M	14.0M	14.0M	14.0M
2020	18.6M	17.1M	15.5M	14.0M
2018	0	6.8M	13.5M	20.2M
2017	158.3K	88.6K	108.8K	93.7K
2016	310.1K	250.5K	190.9K	131.3K
2015	0	0	0	369.7K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Aadi Bioscience, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 01, 2024	desai neil	sold	-77,184	1.9296	-40,000	executive chairman
Apr 02, 2024	desai neil	sold	-49,512	2.2275	-22,228	executive chairman
Apr 01, 2024	desai neil	sold	-41,101	2.3127	-17,772	executive chairman
Mar 04, 2024	desai neil	sold	-31,415	2.0994	-14,964	executive chairman
Mar 01, 2024	desai neil	sold	-53,225	1.9687	-27,036	executive chairman
Feb 01, 2024	desai neil	sold	-73,269	1.7445	-42,000	executive chairman
Jan 02, 2024	desai neil	sold	-86,549	2.0607	-42,000	executive chairman
Dec 06, 2023	desai neil	sold	-33,914	4.8194	-7,037	executive chairman
Dec 05, 2023	desai neil	sold	-78,940	5.0153	-15,740	executive chairman
Dec 04, 2023	desai neil	sold	-55,986	5.1477	-10,876	executive chairman

Which funds bought or sold AADI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 30, 2024	Private Wealth Management Group, LLC	reduced	-58.52	-721	667	-%
Apr 30, 2024	Avior Wealth Management, LLC	new	-	7.00	7.00	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	reduced	-68.87	-6,000	3,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-12.32	1,591	102,628	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-63.36	-2,000	1,000	-%
Apr 22, 2024	Vivo Capital, LLC	unchanged	-	163,063	1,192,400	0.09%
Apr 18, 2024	McGlone Suttner Wealth Management, Inc.	sold off	-100	-32.00	-	-%
Apr 05, 2024	CWM, LLC	unchanged	-	-	-	-%
Mar 22, 2024	PNC Financial Services Group, Inc.	sold off	-100	-1,186	-	-%

Are Funds Buying or Selling AADI?

Are funds buying AADI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AADI

No. of Funds

Unveiling Aadi Bioscience, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	vivo panda, llc	2.1%	509,572	SC 13G/A
Feb 10, 2023	satter muneer a	6.7%	1,630,830	SC 13G/A
Jan 17, 2023	desai neil	10.8%	2,635,196	SC 13D/A
Oct 04, 2022	satter muneer a	5.3%	1,294,785	SC 13G
Sep 26, 2022	avoro capital advisors llc	11.7%	2,849,402	SC 13D/A
Feb 14, 2022	biotechnology value fund l p	2.2%	465,262	SC 13G/A
Feb 14, 2022	venrock healthcare capital partners ii, l.p.	7.3%	1,529,402	SC 13G
Feb 11, 2022	vivo panda, llc	2.8%	575,723	SC 13G/A
Feb 09, 2022	vanguard group inc	3.64%	761,473	SC 13G/A

Recent SEC filings of Aadi Bioscience, Inc.

View All Filings

Date Filed	Form Type	Document
May 01, 2024	4	Insider Trading
Apr 30, 2024	EFFECT	EFFECT
Apr 26, 2024	3	Insider Trading
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 04, 2024	8-K	Current Report
Apr 03, 2024	4	Insider Trading
Mar 13, 2024	10-K	Annual Report
Mar 13, 2024	8-K	Current Report

Peers (Alternatives to Aadi Bioscience, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

Aadi Bioscience, Inc. News

Latest updates

Aadi Bioscience, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2018Q4	2018Q3	2018Q2	2017Q4
Revenue	6.2%	6,326,000	5,959,000	6,202,000	5,867,000	5,227,000	4,245,000	3,437,000	2,307,000	-	-	-	-	-	-	-	15,000,000	7,501,072	2,144	18,821,953	1,333,333	690,079
Costs and Expenses	1.0%	24,040,000	23,808,000	25,747,000	22,692,000	20,698,500	19,281,000	21,797,000	16,121,000	16,944,500	-	87,311,000	3,875,000	4,207,000	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	15,798,388	-	87,311,000	4,771,361	5,602,863	5,060,490	2,894,000	5,744,087	4,114,933	8,868,322	7,623,916	7,369,788	6,288,858
S&GA Expenses	-7.8%	10,345,000	11,221,000	11,776,000	11,207,000	11,107,000	9,915,000	10,006,000	9,148,000	9,717,500	-	7,401,000	830,000	563,000	-1,219,203	499,000	2,195,515	2,285,891	3,619,692	3,277,535	3,140,854	-
R&D Expenses	7.4%	12,768,000	11,890,000	13,315,000	10,956,000	9,369,500	8,773,000	7,726,000	6,794,000	7,227,000	-	5,754,000	3,045,000	3,644,000	6,279,693	2,395,000	3,548,572	1,829,042	5,248,630	4,346,381	4,228,934	-
EBITDA Margin	1.8%	-2.63	-2.68	-2.98	-3.20	-3.95	-5.32	-16.49	-25.36	-97.61	-0.70	-0.42	-0.29	-0.29	-	-	-	-	-	-	-	-
Interest Expenses	-1.7%	57,000	58,000	58,000	58,000	56,500	58,000	58,000	58,000	57,000	-	157,000	227,000	224,000	230,000	229,000	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-9,000	-	9,000	-	-	-	-	2,000	-	-	1,000	-	-	-	-	-	-
Earnings Before Taxes	0.2%	-16,269,000	-16,302,000	-17,971,000	-	-13,922,000	-14,474,000	-18,260,000	-13,857,000	-15,990,000	-	-87,088,000	-1,534,000	-5,476,000	-	-2,891,000	-	-	-	-	-	-
EBT Margin	1.8%	-2.65	-2.69	-3.00	-3.22	-3.98	-5.35	-16.55	-25.51	-98.29	-0.94	-0.55	-0.39	-0.30	-	-	-	-	-	-	-	-
Net Income	0.2%	-16,269,000	-16,302,000	-17,971,000	-15,223,000	-13,913,000	-14,474,000	-18,269,000	-13,857,000	-15,990,000	-	-87,088,000	-1,536,000	-5,476,000	8,020,000	-2,892,000	-5,282,000	-3,324,000	-8,518,590	11,537,478	-5,989,992	-
Net Income Margin	1.0%	-2.70	-2.73	-2.86	-3.30	-3.98	-5.35	-16.55	-25.51	-98.29	-23.29	-13.72	-0.21	-0.49	-	-	-	-	-	-	-	-
Free Cashflow	19.8%	-10,460,000	-13,049,000	-17,447,000	-22,679,000	-11,388,000	-8,297,000	-10,961,000	-19,438,000	-12,474,000	-17,373,000	-17,373,000	-3,185,000	10,563,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-5.2%	132	140	151	171	184	194	129	142	158	169	37.00	41.00	19.00	50.00	46.00	36.00	40.00	46.00	50.00	55.00	64.00
Current Assets	-6.2%	125	133	145	165	180	190	124	136	151	162	37.00	41.00	19.00	50.00	45.00	35.00	40.00	45.00	49.00	54.00	64.00
Cash Equivalents	-8.6%	63.00	69.00	68.00	34.00	39.00	135	119	130	149	161	37.00	39.00	4.00	47.00	45.00	35.00	39.00	43.00	48.00	53.00	63.00
Inventory	77.8%	6.00	4.00	3.00	4.00	2.00	1.00	1.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	33.4%	5.00	4.00	3.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	26.9%	27.00	21.00	20.00	25.00	26.00	25.00	20.00	18.00	22.00	18.00	2.00	2.00	31.00	3.00	3.00	3.00	3.00	4.00	4.00	4.00	5.00
Current Liabilities	28.6%	26.00	21.00	13.00	18.00	19.00	18.00	13.00	12.00	15.00	12.00	2.00	2.00	30.00	3.00	3.00	3.00	3.00	4.00	4.00	4.00	5.00
Shareholder's Equity	-11.0%	105	118	131	146	158	169	109	125	136	151	35.00	39.00	43.00	47.00	43.00	33.00	37.00	42.00	46.00	51.00	59.00
Retained Earnings	-6.5%	-269	-252	-236	-218	-203	-189	-174	-156	-142	-126	-155	-150	-32.59	-141	-136	-146	-142	-137	-133	-127	-118
Additional Paid-In Capital	0.9%	374	371	368	364	362	358	284	281	279	278	191	190	20.00	189	179	179	179	179	179	178	178
Shares Outstanding	0.1%	25.00	25.00	25.00	24.00	24.00	21.00	21.00	21.00	21.00	10.00	3.00	3.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	111	-	-	-	178	-	-	-	60.00	-	-	-	49.00	-	-	-	26.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	19.3%	-9,644	-11,951	-16,758	-21,310	-11,310	-8,195	-10,720	-19,415	-12,428	-17,373	-3,185	10,563	-3,275	-15,777	10,292	-3,939	-4,865	-4,763	-5,146	-9,078	-6,184
Share Based Compensation	2.0%	3,111	3,049	3,054	2,740	2,870	2,757	2,235	1,781	1,383	648	39.00	36.00	-245	34.00	308	327	-786	646	605	622	668
Cashflow From Investing	-71.2%	3,649	12,667	50,561	16,329	-84,379	-48,243	-241	-23.00	-46.00	25,356	-	-	-	-6.83	-	-	1*	-4.28	-119	-113	-8.53
Cashflow From Financing	206.7%	80.00	-75.00	313	8.00	-107	72,516	-87.00	298	88.00	141,717	-71.28	70.00	-	-	-	-	-	-	-	-	76*
Dividend Payments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AADI Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Total revenue	$ 24,354,000	$ 15,216,000
Operating expenses
Selling, general and administrative	44,549,000	40,176,000
Research and development	48,929,000	32,662,000
Cost of goods sold	2,809,000	1,335,000
Impairment of acquired contract intangible asset	0	3,724,000
Total operating expenses	96,287,000	77,897,000
Loss from operations	(71,933,000)	(62,681,000)
Other income (expense)
Foreign exchange loss	(1,000)	0
Interest income	6,400,000	2,398,000
Interest expense	(231,000)	(230,000)
Total other income, net	6,168,000	2,168,000
Loss before income tax expense	(65,765,000)	(60,513,000)
Income tax expense	0	0
Net loss	(65,765,000)	(60,513,000)
Other comprehensive income (loss):
Unrealized income (loss) on available-for-sale debt securities	142,000	(115,000)
Comprehensive loss	$ (65,623,000)	$ (60,628,000)
Net loss per share, basic (in dollars per share)	$ (2.44)	$ (2.69)
Net loss per share, diluted (in dollars per share)	$ (2.44)	$ (2.69)
Weighted average number of common shares outstanding, basic (in shares)	26,917,967	22,511,237
Weighted average number of common shares outstanding, diluted (in shares)	26,917,967	22,511,237
Product sales, net
Total revenue	$ 24,354,000	$ 15,216,000

AADI Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 62,888	$ 39,019
Short-term investments	45,957	133,541
Accounts receivable, net	5,488	1,862
Inventory	6,427	1,861
Prepaid expenses and other current assets	3,826	3,746
Total current assets	124,586	180,029
Property and equipment, net	4,802	508
Operating lease right-of-use assets	1,169	1,522
Other assets	1,866	2,178
Total assets	132,423	184,237
Current liabilities:
Accounts payable	5,898	3,519
Accrued liabilities	14,306	14,922
Operating lease liabilities, current portion	434	394
Due to licensor payable (Note 8)	5,757	0
Total current liabilities	26,395	18,835
Operating lease liabilities, net of current portion	833	1,267
Due to licensor (Note 8)	0	5,757
Total liabilities	27,228	25,859
Commitments and contingencies (Note 13)
Stockholders’ equity:
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2023 and 2022	0	0
Common stock, $0.0001 par value, 300,000,000 shares authorized; 24,554,205 and 24,435,007 shares issued and outstanding as of December 31, 2023 and 2022, respectively	2	2
Additional paid-in capital	374,129	361,689
Accumulated other comprehensive income (loss)	27	(115)
Accumulated deficit	(268,963)	(203,198)
Total stockholders’ equity	105,195	158,378
Total liabilities and stockholders’ equity	$ 132,423	$ 184,237

About Aadi Bioscience, Inc.

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus bound to albumin. The company is also involved in evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

CEO	Mr. Scott M. Giacobello CPA
WEBSITE	https://aadibio.com
INDUSTRY	Biotechnology
EMPLOYEES	89

Aadi Bioscience, Inc. Frequently Asked Questions

What is the ticker symbol for Aadi Bioscience, Inc.? What does AADI stand for in stocks?

AADI is the stock ticker symbol of Aadi Bioscience, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aadi Bioscience, Inc. (AADI)?

As of Thu May 02 2024, market cap of Aadi Bioscience, Inc. is 49.6 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AADI stock?

You can check AADI's fair value in chart for subscribers.

What is the fair value of AADI stock?

You can check AADI's fair value in chart for subscribers. The fair value of Aadi Bioscience, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aadi Bioscience, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AADI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aadi Bioscience, Inc. a good stock to buy?

The fair value guage provides a quick view whether AADI is over valued or under valued. Whether Aadi Bioscience, Inc. is cheap or expensive depends on the assumptions which impact Aadi Bioscience, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AADI.

What is Aadi Bioscience, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, AADI's PE ratio (Price to Earnings) is -0.75 and Price to Sales (PS) ratio is 2.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AADI PE ratio will change depending on the future growth rate expectations of investors.